Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefoperazone/sulbactam PK/PD in MDR nonfermentative bacilli HAP
ChiCTR-OPN-16008848Phase 4Completed
- Sponsor
- Huashan Hospital
- Start
- Jan 2009
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cefoperazone + sulbactam in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), Pseudomonas pneumonia and 1 more (4 arms), sponsored by Huashan Hospital. Primary endpoints: plasma concentration of cefoperazone, plasma concentration of sulbactam and 5 more. Started Jan 2009; status: completed.
02
Drugs
cefoperazone + sulbactam
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Pseudomonas pneumoniaAcinetobacter pneumonia
Beyond the preview
Go deeper on ChiCTR-OPN-16008848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPN-16008848.